Cargando…
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Risankizumab (Skyrizi(®); risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475056/ https://www.ncbi.nlm.nih.gov/pubmed/32632826 http://dx.doi.org/10.1007/s40265-020-01357-1 |
_version_ | 1783579443634110464 |
---|---|
author | Blair, Hannah A. |
author_facet | Blair, Hannah A. |
author_sort | Blair, Hannah A. |
collection | PubMed |
description | Risankizumab (Skyrizi(®); risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (in the EU), those who are candidates for systemic therapy or phototherapy (in the USA) and those who have an inadequate response to conventional therapies (in Japan). In pivotal phase III trials (UltIMMa-1, UltIMMa-2, IMMvent and IMMhance), risankizumab was more effective than placebo, ustekinumab and adalimumab with regard to the proportion of patients achieving ≥ 90% improvement from baseline in Psoriasis Area and Severity Index score (PASI 90) and a static Physician’s Global Assessment score of 0 or 1 at week 16, with these benefits maintained over the longer term. In supportive head-to-head trials, risankizumab was also superior to secukinumab and fumaric acid esters in terms of PASI 90 response rate. In an ongoing open-label extension study (LIMMitless), risankizumab was associated with durable and improved efficacy after switching from ustekinumab or adalimumab, as well as durable maintenance of efficacy through > 2.5 years of continuous exposure. Treatment with risankizumab improved health-related quality of life and was generally well tolerated, both in the short- and longer-term. In conclusion, risankizumab represents a useful new treatment option for patients with moderate to severe plaque psoriasis. |
format | Online Article Text |
id | pubmed-7475056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-74750562020-09-16 Risankizumab: A Review in Moderate to Severe Plaque Psoriasis Blair, Hannah A. Drugs Adis Drug Evaluation Risankizumab (Skyrizi(®); risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (in the EU), those who are candidates for systemic therapy or phototherapy (in the USA) and those who have an inadequate response to conventional therapies (in Japan). In pivotal phase III trials (UltIMMa-1, UltIMMa-2, IMMvent and IMMhance), risankizumab was more effective than placebo, ustekinumab and adalimumab with regard to the proportion of patients achieving ≥ 90% improvement from baseline in Psoriasis Area and Severity Index score (PASI 90) and a static Physician’s Global Assessment score of 0 or 1 at week 16, with these benefits maintained over the longer term. In supportive head-to-head trials, risankizumab was also superior to secukinumab and fumaric acid esters in terms of PASI 90 response rate. In an ongoing open-label extension study (LIMMitless), risankizumab was associated with durable and improved efficacy after switching from ustekinumab or adalimumab, as well as durable maintenance of efficacy through > 2.5 years of continuous exposure. Treatment with risankizumab improved health-related quality of life and was generally well tolerated, both in the short- and longer-term. In conclusion, risankizumab represents a useful new treatment option for patients with moderate to severe plaque psoriasis. Springer International Publishing 2020-07-06 2020 /pmc/articles/PMC7475056/ /pubmed/32632826 http://dx.doi.org/10.1007/s40265-020-01357-1 Text en © Springer Nature 2020, corrected publication 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Adis Drug Evaluation Blair, Hannah A. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis |
title | Risankizumab: A Review in Moderate to Severe Plaque Psoriasis |
title_full | Risankizumab: A Review in Moderate to Severe Plaque Psoriasis |
title_fullStr | Risankizumab: A Review in Moderate to Severe Plaque Psoriasis |
title_full_unstemmed | Risankizumab: A Review in Moderate to Severe Plaque Psoriasis |
title_short | Risankizumab: A Review in Moderate to Severe Plaque Psoriasis |
title_sort | risankizumab: a review in moderate to severe plaque psoriasis |
topic | Adis Drug Evaluation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475056/ https://www.ncbi.nlm.nih.gov/pubmed/32632826 http://dx.doi.org/10.1007/s40265-020-01357-1 |
work_keys_str_mv | AT blairhannaha risankizumabareviewinmoderatetosevereplaquepsoriasis |